BiotechTube
Home/Cynata Therapeutics/Dr. Kilian Kelly
DK

Dr. Kilian Kelly

Chief Operating Officer

Cynata Therapeutics

Therapeutic Areas

ImmunologyMusculoskeletalCardiovascularDermatology

Cynata Therapeutics Pipeline

DrugIndicationPhase
CYP-001Steroid-Resistant Acute Graft-Versus-Host Disease (GvHD)Phase 2
CYP-004Osteoarthritis (Knee)Phase 3
CYP-006Diabetic Foot UlcersPreclinical

Leadership Team at Cynata Therapeutics

DR
Dr. Ross Macdonald
Chief Executive Officer
View full Cynata Therapeutics profile